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Abstract
Background: Even though there are continually upgraded recommendations for managing sepsis, such as
“Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock”, mortality
is still high. Si-Ni-Tang, a remedy documented in Shanghan Lun, a medical collection from ancient China, is used
for treating patients with sepsis and septic shock. Using a well-designed clinical trial, we are eager to survey the
effectiveness of the concurrent use of this remedy in restoring these patients’ hemodynamic status, or “Yang Qi”.
Methods/Design: Patients admitted to our medical intensive care units with the diagnosis of septic shock, defined
as persistent hypotension induced by sepsis despite adequate fluid resuscitation, are eligible for participation. The
inclusion criteria include: age from 20 to 85 years, conditions meeting the definition of septic shock, use of
vasopressors within 24 hours of entering the study, and use of a nasogastric tube for feeding. The enrolled patients
are randomly allocated either to the Si-Ni-Tang group or the placebo group. The prescription of the trial drugs (Si-Ni-
Tang/placebo) is 2.25 grams 4 times a day for 7 days or till shock reversal (if shock reversal occurs in less than 7 days).
Data, including duration of vasopressor infusion, gender, age, co-morbidities, APACHE II score, predicted mortality,
ICU mortality, ICU length of stay, hospital mortality, hospital length of stay, source of sepsis, and culture results, are
collected for the following analysis.
Discussion: Si-Ni-Tang is composed of processed Zingiber officinale, Glycyrrhiza uralensis, and Aconitum carmichaeli.
Zingiber officinale and Glycyrrhiza uralensis are found to have the ability to reduce pro-inflammatory cytokine
production, to inhibit lipopolisaccharide-induced macrophage activation and function, and to lessen the bacterial
load and suppress acute and chronic inflammation. Aconitum carmichaeli is known to have vasopressor activity,
and positive chronotropic and inotropic effects. As this remedy has a potential benefit in treating septic shock
patients, we designed a double-blind, prospective, randomized controlled trial and would like to publish the results
and conclusions later.
Trial Registration: ClinicalTrials.gov: NCT01223430
Background
Sepsis is an infectious disease, usually caused by bacter-
ial infection, with systemic manifestations. Severe sepsis
is defined as sepsis with organ dysfunction or tissue
hypoperfusion related to sepsis. If the disease progresses
to persistent hypotension, even with adequate fluid
resuscitation, the presentation is known as septic shock.
Severe sepsis, and if further deteriorated, septic shock,
are important issues for healthcare workers. Even though
the recommendations for managing sepsis and septic
shock, such as “Surviving Sepsis Campaign: international
guidelines for management of severe sepsis and septic
shock” [1], are continually upgraded, mortality due to
* Correspondence: 97987@cch.org.tw
2Division of Critical Care Medicine, Department of Internal Medicine,
Changhua Christian Hospital, Changhua, Taiwan
Full list of author information is available at the end of the article
Chen et al. Trials 2011, 12:199
http://www.trialsjournal.com/content/12/1/199 TRIALS
© 2011 Chen et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.sepsis and septic shock in the intensive care units is still
high.
We may not know initially the exact etiology of the
septic shock when treating the patients, but maintaining
an adequate hemodynamic status in order to keep these
patients with organ perfusion well is always the main
issue for intensivists.
The history of Chinese medicine can be traced back
thousands of years. Certainly, the theory and application
of Chinese medicine in treating patients with severe
infection have been documented in several Chinese med-
ical books. The presentation of the septic shock patient is
characterized as “depletion of Yang Qi”, meaning little
energy and very weak pulse.
When treating patients diagnosed with septic shock, the
optimal approach we will take will be to follow recently
proposed guidelines. However, there is still much research
devoted to finding a better way to improve patient out-
come. Herbal or Chinese medicine has been investigated
in the treatment of infectious disease and shock [2]. Many
remedies to treat sepsis or septic shock have been docu-
mented in ancient Chinese medical books or literature.
Si-Ni-Tang, for example, documented in Shanghan Lun, a
medical collection from ancient China, is used for treating
patients with shock, heart failure, severe watery diarrhea
and poor extremity circulation. It is considered a good
choice to treat patients who suffer from infectious disease
complicated with hemodynamic instability.
Si-Ni-Tang is manufactured from and composed of
processed Zingiber officinale, Glycyrrhiza uralensis,a n d
Aconitum carmichaeli. Using a well-designed clinical
trial, we are eager to survey the effectiveness of concur-
rent use of this remedy in restoring “Yang Qi”. That is to
say, we want to know whether Si-Ni-Tang can shorten
the duration of the shock status. The purpose of this
study is to determine whether the simultaneous use of a
traditional Chinese medicine, Si-Ni-Tang, is more effec-
tive in the treatment of septic shock patients. Only by
conscientiously performing studies and pursuing positive
outcomes can we push Chinese medicine onto the stage.
Certainly, finding the best way to benefit people and
patients with septic shock is the ultimate goal of our
study.
Methods/Design
The study is designed as a double-blind, prospective,
randomized controlled trial. It has been approved by the
ethics committee. Our study procedures and informed
consent were reviewed by the Institutional Review
Board of Changhua Christian Hospital beginning in Jan.
2010. There were four revisions before the study proce-
dures and informed consents were finally approved by
the third Institutional Review Board Committee on Aug.
10, 2010.
All participating patients are randomized using a com-
puterized block randomization schedule with a multiple
block size of four. 120 patients (30 blocks) were randomly
(same chance) generated that were kept in sequentially
numbered opaque envelopes. Researchers and patients are
blinded to treatment allocation; the only un-blinded indi-
vidual is the statistician responsible for randomization pro-
cess. The treatment assignments are balanced within each
block. Each block contains 4 patients with 2 patients for
Si-Ni-Tang group, and 2 patients for placebo group (same
chance).
Our study is directed by the Graduate Institute of Inte-
grated Medicine, College of Chinese Medicine, China
Medical University and is conducted in the medical inten-
sive care units in Changhua Christian Hospital, a medical
center in central Taiwan. The drugs used in the trial,
whether Si-Ni-Tang or placebo, are both manufactured
and provided by a pharmaceutical company that meet the
requirements of Good Manufacturing Practice. All impor-
tant drug information, including ingredient composition,
heavy metals, etc., is provided by the same company.
According to the GUIDELINE ON CLINICAL TRIAL
OF NEW CHINESE MEDICINE promulgated by the
Department of Health, Executive Yuan, Taiwan on Feb. 5,
2008, we are allowed to investigate directly the therapeutic
efficacy of the Chinese medicines listed in classical Chi-
nese pharmacopoeias, due to the long-term experience
and widespread clinical use of these medicines. The drug
used in our trial, Si-Ni-Tang, an example of Chinese medi-
cines listed in classical Chinese pharmacopoeias, is
regarded as safe and effective for patients with shock.
However, it has been criticized for lacking adequate eva-
luation through clinical trials supported and conducted
according to the principles of modern clinical trials. To
evaluate the actual benefit and the possible risk, we
designed this double-blind, prospective, randomized con-
trolled trial.
Our study is being carried out somewhat like phase 2
studies in clinical trials. Phase 2 studies are set forth to
evaluate the effectiveness of drugs in participants with a
certain disease or condition. We assume that the mean
duration of vasopressor use of the Si-Ni-Tang group is 3
hours shorter than that of the placebo group, with a stan-
dard deviation of 6.5 hours. Under the setting of alpha =
.05 and power = 80%, the calculated sample size of each
g r o u pi sa r o u n d6 0 .T h i si sw h yw ep l a nt oe n r o l l1 2 0
participants.
Sepsis is an infectious disease, usually caused by bacter-
ial infection, with systemic manifestations. Sepsis-induced
hypotension is defined as a systolic blood pressure less
than 90 mmHg or mean arterial pressure less than
70 mmHg. Septic shock is defined as persistent hypoten-
sion induced by sepsis, despite adequate fluid resuscita-
tion. We plan to enroll 120 patients who have been
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nosis of septic shock. The flow chart of the study is illu-
strated as Figure 1.
Eligible patients must fulfill all the following require-
ments: age from 20 to 85 years, a disease diagnosis
meeting the definition of septic shock, use of vasopres-
sors now and an initiation of vasopressor use within 24
hours of entering the study, use of a nasogastric tube
for feeding, and informed consent obtained from either
the patients or their relatives.
Exclusion criteria are an extremely poor gastrointestinal
function and an inability to tolerate diet feeding, acute
myocardial infarction, evidence of major bleeding, expected
or scheduled surgical intervention in the subsequent one
week, use of 2 or more than 2 kinds of vasopressors upon
entrance into the study, and patients who have received
digoxin for arrhythmia within the past one week.
The treatment for the patients with septic shock in
our hospital adheres to the Surviving Sepsis Campaign:
International guidelines for management of severe sepsis
and septic shock 2008. Our study uses block randomiza-
tion with a block size of 4 and an allocation ratio of 1:1.
After enrolment, the eligible patients are either allocated
to the Si-Ni-Tang group or the placebo group. The pre-
scription of the trial drugs is 2.25 grams 4 times a day
(9 grams per day) for 7 days or till shock reversal (if
shock reversal occurs in less than 7 days). Shock reversal
is defined as the discontinuation of norepinephrine or
dopamine for at least 24 hours.
We will collect the following data from each partici-
pant: gender, age, co-morbidities, APACHE II score,
predicted mortality, ICU mortality, ICU length of stay,
hospital mortality, hospital length of stay, source of sep-
sis (pulmonary, gastrointestinal, renal or others), culture
results (Gram-positive, Gram-negative or mixed) and
duration of vasopressor infusion. Shock reversal and
time to cessation of vasopressor use would be the pri-
mary outcome measurements.
5DQGRPL]DWLRQ
Q 
$VVHVVHGIRU
HOLJLELOLW\Q!
([FOXGHGQ 
1RWPHHWLQJLQFOXVLRQFULWHULDQ 
'HFOLQHGWRSDUWLFLSDWHQ 
2WKHUUHDVRQVQ 
$OORFDWHGWR 3ODFHER Q 
5HFHLYHGDOORFDWHGLQWHUYHQWLRQQ 
'LGQRWUHFHLYHDOORFDWHGLQWHUYHQWLRQQ 
$QDO\VHG
Q 
'LVFRQWLQXHG
LQWHUYHQWLRQ
Q 
$OORFDWHGWR 6L1L7DQJ Q 
5HFHLYHGDOORFDWHGLQWHUYHQWLRQQ 
'LGQRWUHFHLYHDOORFDWHGLQWHUYHQWLRQQ 
$QDO\VHG
Q 
'LVFRQWLQXHG
LQWHUYHQWLRQ
Q 
Figure 1 Enrolment Flowchart. The figure illustrates how the participants are enrolled and allocated.
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the two groups using the Student’st - t e s tf o ru n p a i r e d
data for the comparison of continuous variables and the
Pearson’s chi-squared test to compare categorical
variables.
The effect of Si-Ni-Tang treatment on time to cessation
of vasopressor use is estimated, first, from Kaplan-Meier
curves and log-rank test for median time, and second,
from adjusted Cox proportional hazards regression models
for potential confounders (age, APACHE II score at base-
line, source of sepsis, co-morbidities). Corresponding
hazard ratios along with their 95% confidence intervals are
reported. Patients who died before cessation of vasopres-
sor use are treated as censored. Analysis is performed on
the intention to treat population.
There is no planned subgroup analysis anticipated. Only
primary and secondary outcome measures will be ana-
lyzed. However, all of the variables which are found to be
important predictors of shock reversal and adverse out-
come will be used for stratifications for post-hoc analysis
(relative risks will be estimated for the major outcomes
using multivariate Poisson regression adjusting for
covariates).
Discussion
Septic shock, usually caused by bacterial infection, is a
severe systemic inflammatory consequence leading to
multi-organ dysfunction. As with acute myocardial infarc-
tion, stroke and multiple trauma, treatment guidance for
severe sepsis and septic shock in the initial period has
been developed. Even though treatment recommendations
are continually upgraded, mortality from sepsis and septic
shock in the intensive care units is still high. Many reme-
dies using herbal or traditional Chinese medicine have
been proven to be potential adjuvant therapies in the
treatment of sepsis and septic shock.
Si-Ni-Tang is composed of processed Zingiber offici-
nale, Glycyrrhiza uralensis,a n dAconitum carmichaeli.
Zingiber officinale extract is found to have the ability to
inhibit pro-inflammatory cytokines [3] and lipopolisac-
charide-induced macrophage activation and function [4],
and to reduce the bacterial load and suppress acute and
chronic inflammation [5]. Glycyrrhiza uralensis extract is
also considered to have anti-inflammatory properties and
reduce lipopolysaccharide-induced pro-inflammatory
cytokine secretion [6-8]. “Fuzi”, the lateral root tuber of
processed Aconitum carmichaeli, is used for treating
pain, arthritis, cardiogenic shock, rheumatism, etc., in
traditional Chinese medicine. Aconite roots are used only
after processing and the procedure can hydrolyze aconite
alkaloids into less toxic and non-toxic derivatives [9].
Aconite roots may contain coryneine chloride and higen-
amine, and possess vasopressor activity and positive
chronotropic and inotropic effects [10,11]. Without a
doubt, “Fuzi”, Aconitum carmichaeli, is the critical factor
in the remedy, Si-Ni-Tang.
Each component of Si-Ni-Tang is considered to be
beneficial to septic shock patients, as described above.
However, the most important theory of the Chinese med-
icine prescription is that there is a leading, coordinating,
auxiliary and guiding effect in the remedy component.
Perhaps, the exact benefit and effect of the drug combi-
nation go beyond what we already know. Only via con-
scientiously performed studies and positive outcomes can
we push Chinese medicine onto the stage. And again,
benefiting people and patients with septic shock is always
the ultimate goal of our research. The clinical trial is
being conducted now. If there are any conclusions in the
near future, we would like to publish them later.
List of abbreviations
APACHE II: Acute Physiology and Chronic Health Evaluation II; ICU: Intensive
Care Unit.
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